Nantkwest Inc (NASDAQ:NK)’s share price traded up 3.2% during trading on Monday . The company traded as high as $1.69 and last traded at $1.63, 3,101 shares were traded during mid-day trading. A decline of 99% from the average session volume of 292,311 shares. The stock had previously closed at $1.58.
Separately, ValuEngine downgraded Nantkwest from a “buy” rating to a “hold” rating in a research note on Friday, November 29th.
The company has a current ratio of 5.72, a quick ratio of 5.72 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $1.24 and its 200 day moving average is $1.20. The company has a market cap of $162.30 million, a PE ratio of -1.37 and a beta of 2.52.
Nantkwest (NASDAQ:NK) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The business had revenue of $0.01 million for the quarter. Nantkwest had a negative net margin of 164,604.89% and a negative return on equity of 44.91%.
A number of hedge funds have recently bought and sold shares of NK. Parametric Portfolio Associates LLC purchased a new position in Nantkwest in the 2nd quarter valued at $37,000. Morgan Stanley boosted its stake in Nantkwest by 303.8% during the 2nd quarter. Morgan Stanley now owns 48,497 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 36,486 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Nantkwest by 4,218.8% during the third quarter. Tower Research Capital LLC TRC now owns 47,766 shares of the biotechnology company’s stock worth $58,000 after buying an additional 46,660 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Nantkwest during the second quarter worth $92,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Nantkwest in the second quarter valued at about $127,000. Institutional investors own 5.47% of the company’s stock.
Nantkwest Company Profile (NASDAQ:NK)
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Featured Article: Diversification in Investing
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.